Erythropoietic protoporphyria gene therapy

Drug Profile

Erythropoietic protoporphyria gene therapy

Latest Information Update: 08 Jul 2003

Price : $50

At a glance

  • Originator Genetix Pharmaceuticals
  • Developer Genetix Pharmaceuticals; Nonindustrial source
  • Class Gene therapies
  • Mechanism of Action Ferrochelatase synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Erythropoietic protoporphyria

Most Recent Events

  • 08 Jul 2003 Discontinued - Preclinical for Erythropoietic protoporphyria in USA (Unspecified)
  • 27 Sep 1999 Preclinical development for Erythropoietic protoporphyria in USA (Unspecified)
  • 27 Sep 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top